Triple-action diabetes jab shown to reduce blood sugar and body weight
Retatrutide is designed to control appetite and blood sugar but also increase body’s energy expenditure, unlike other drugs A new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results . Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placeb…


